Clinical Trial Update: A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for OR502, a monoclonal antibody targeting LILRB2, studied alone and with anticancer agents in Phase 1/2; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• OR502

Snippet

Sponsor: OncoResponse, Inc. | Conditions: Cancer, Tumor, Solid | Phase 1, Phase 2 | Status: RECRUITING